Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VRDN
VRDN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VRDN News
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
Dec 31 2025
Benzinga
Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease
Dec 23 2025
NASDAQ.COM
Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics
Dec 15 2025
Benzinga
Viridian Therapeutics Grants 171,900 Stock Options to New Employees
Dec 05 2025
Newsfilter
Analyst Predicts Viridian's New Thyroid Eye Treatment May Surpass Amgen's Tepezza
Dec 03 2025
Benzinga
Viridian Metals Closes First Tranche of $591,543 Private Placement
Dec 02 2025
Globenewswire
RBC Capital Maintains Positive Outlook on Viridian Therapeutics (VRDN) After Q3 2025 Performance
Nov 17 2025
Yahoo Finance
Viridian Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Nov 07 2025
Newsfilter
RBC Capital Reaffirms Outperform Rating for Viridian Therapeutics and Increases Price Target to $45
Nov 06 2025
Benzinga
Viridian Shares Drop 8.6% Following $251 Million Public Offering
Oct 22 2025
NASDAQ.COM
Viridian Therapeutics Sets Price for $251 Million Public Stock Offering
Oct 22 2025
Newsfilter
Top Analysts Recommend 3 Best Stocks to Purchase Now, 10/21/2025
Oct 21 2025
TipRanks
Viridian Therapeutics Secures Up to $300 Million in Royalty Financing from DRI Healthcare
Oct 20 2025
Newsfilter
Viridian Therapeutics Reports Full Enrollment in REVEAL Clinical Trials and Positive Developments in Portfolio
Sep 15 2025
Newsfilter
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Aug 07 2025
Benzinga
Goldman Sachs Maintains Buy on Viridian Therapeutics, Raises Price Target to $30
Aug 07 2025
Benzinga
Show More News
